HC Wainwright & Co. Maintains Buy on InflaRx, Raises Price Target to $8
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Matthew Keller maintains InflaRx (NASDAQ:IFRX) with a Buy and raises the price target from $6 to $8.
HC Wainwright & Co. analyst Matthew Keller maintains InflaRx (NASDAQ:IFRX) with a Buy and raises the price target from $6 to $8.